share_log

復宏漢霖(02696.HK)私有化告吹 復星醫藥(02196.HK)稱將一如既往地支持其發展

HENLIUS (02696.HK) privatization has failed, and FOSUN PHARMA (02196.HK) stated that it will continue to support its development.

AASTOCKS ·  Jan 23 01:35

FOSUN PHARMA (02196.HK) failed to pass the special resolution for the merger by absorption to privatize HENLIUS (02696.HK), and the merger will not be implemented. HENLIUS will retain its Listed in Hong Kong status. FOSUN PHARMA expressed regret and stated that it will fully respect the decisions of all Shareholders and will continue to support HENLIUS's long-term healthy development in the future.

FOSUN PHARMA also indicated that HENLIUS retaining its Listed in Hong Kong status reflects investors' Bullish outlook on HENLIUS and the future prospects of the Biomedical industry. It believes that both the China and Global Biomedical markets are full of opportunities. FOSUN PHARMA insists on innovation-driven approaches, focusing on unmet clinical needs, and strengthening core technology platforms such as antibodies/ADCs, cell therapy, and small molecules. At the same time, it will firmly support HENLIUS as an antibody technology platform, continuing to deepen innovative R&D in the field of biopharmaceuticals, expanding domestic and international markets, and further enhancing Global competitiveness.

As of now, FOSUN PHARMA indirectly holds 59.56% equity in HENLIUS.

HENLIUS (02696.HK) opened down 10.5% this morning (23rd), initially reaching a low of 15.2 yuan before narrowing the decline. The latest report is 16.64 yuan, down 2.7%, with a turnover of 29.4813 million yuan. FOSUN PHARMA (02196.HK) is currently reported at 13.4 yuan, up 2.76%, with a turnover of 9.81 million yuan.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 440

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.